Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform

May 19, 2020 7:35 AM

- Represents significant milestone in strategic development plan to advance XCART through academic collaborations - - Provides access to leading research institution with world renowned immunology expertise - - Company engaged in ongoing discussions to potentially add additional academic and development collaborators - FRAMINGHAM, MA / ACCESSWIRE / May 19, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the...

Read more

Materna Medical Launches New Website to Empower More Women and Clinicians

May 19, 2020 6:01 AM

Bringing gradual, simple solutions to an underserved market of women across the U.S. MOUNTAIN VIEW, CA / ACCESSWIRE / May 19, 2020 / Materna Medical (Materna), a MedTech company developing products to help protect women's pelvic health, has launched a new website for Milli™, an all-in-one vaginal trainer, empowering women to overcome vaginal tightness in an easy, comfortable, and convenient way. Milli's new website will also...

Read more

Midatech Pharma PLC Announces UK Placing to Raise £1.8 million

May 18, 2020 10:20 AM

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH...

Read more

Midatech Pharma PLC Announces US$3.0 Million Registered Direct Offering

May 18, 2020 9:40 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 18, 2020 / Midatech Pharma PLC ("Midatech" or the "Company") (AIM:MTPH.L; NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has entered into definitive binding agreements with institutional investors (the "Investors") for the purchase in a registered direct offering...

Read more

Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines

May 18, 2020 6:00 AM

Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine Baylor College of Medicine in Texas has developed SARS-CoV and SARS-CoV-2 recombinant proteins and has extensive expertise developing protein-based vaccines from discovery through clinical...

Read more

Two Quebec Companies Joined Forces to Make Healthcare Mask for our "Guardian Angels"

May 15, 2020 11:00 AM

OTTAWA, ON / ACCESSWIRE / May 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development and ARTOFIX a Quebec City based high performance mask manufacturer are pleased to announce that Tetra has secured a Medical Device Establishment License (MDEL) for a Class 1 medical device manufacturer for Artofix. This will allow Artofix to...

Read more

Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results

May 15, 2020 8:00 AM

TORONTO, ON / ACCESSWIRE / May 15, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended March 31, 2020 and provided an update on its business. Edesa reported that two new biologic drug candidates acquired last month are rapidly being integrated into the company's development pipeline. Known as EB05 and EB06, these TLR4 and CXCL10...

Read more

Molecular Partners to Present Preclinical Data from MP0317, AMG 506 / MP0310 and Peptide-MHC Programs at AACR Annual Meeting

May 15, 2020 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 15, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced the presentation of preclinical data from three of the company's programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting II, June 22-24, 2020. Data to be presented on...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 14, 2020 4:05 PM

- Company poised to execute on near- and long-term value-driving milestones to advance preclinical development of its XCART™ CAR T therapy platform - - Continuing to progress discussions to secure academic collaborations to advance the XCART platform - - Cash on hand expected to fund operations through mid-2021 - FRAMINGHAM, MA / ACCESSWIRE / May 14, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or...

Read more

Dyadic Reports 2020 First Quarter Results and Recent Developments

May 14, 2020 4:00 PM

Two fully funded research projects with top four animal health companies.Nonexclusive research license agreement with WuXi Biologics.Feasibility study with the University of Oslo on influenza vaccine.Engineered C1 cell lines to produce high levels of potential SARS-CoV-2 vaccines.Strategic R&D relationships to assist in the development of potential COVID-19 vaccines and antibodies.Cash and investment grade securities of $34 million at end of...

Read more

Tetra Announces Resignation of President

May 13, 2020 12:00 PM

OTTAWA, ON / ACCESSWIRE / May 13, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, announces that its Board of Directors has accepted the resignation of Mr. Sylvain Chretien as President of the Company. In light of Mr. Chretien's resignation, the Board has decided not to appoint another president at this time. Due to...

Read more

Covid-19:15 Second Home Testing GenViro! Swift Kit Identified By Largest CBS Affiliate In The Country As Potential Testing Solution To Help Get Country Back To Work

May 12, 2020 9:10 AM

WCBS-TV REPORT BY CHIEF HEALTH AND MEDICAL REPORTER DR. MAX GOMEZ, ALSO PICKED UP ON YAHOO NEWS, THEREBY REACHING A TOTAL AUDIENCE OF OVER 13 MILLION LOS ANGELES, CA / ACCESSWIRE / May 12, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc. the manufacturers and design specifiers for the GenViro! Covid-19 :15 test professional Swift Kit, today announced that it received detailed media...

Read more

Hancock Jaffe Announces Plans for CoreoGraft First-in-Human Study

May 12, 2020 8:30 AM

CoreoGraft Study Approved by the Superintendent of Health of the National Health Council of Paraguay IRVINE, CA / ACCESSWIRE / May 12, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has received approval from the Superintendent of Health of the National Health Counsel for the Republic of Paraguay to conduct a first-in-human study...

Read more

Tetra Bio-Pharma Provides Update on PPP003 Inflammatory Cytokine Reduction Drug Program

May 11, 2020 12:00 PM

OTTAWA, ON / ACCESSWIRE / May 11, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that its Chief Operating Officer Steeve Néron participated in an interview on Saturday to discuss the Company's development of a drug program to treat certain symptoms of COVID-19. As mentioned in previous...

Read more

Tetra Bio-Pharma Obtains Health Canada Approval for Renewal of its Veterinary Clinical Study

May 11, 2020 8:00 AM

No adverse events observed in study participants Health Canada VDD grants trial renewal OTTAWA, ON / ACCESSWIRE / May 11, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF) , a leader in cannabinoid-derived drug discovery and development, is pleased to announce that its pilot clinical study to evaluate the tolerability and potential efficacy of its PPP003 ophthalmic drug in the treatment of...

Read more

Pieris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 11, 2020 7:00 AM

Company to Host an Investor Conference Call on Monday, May 11, 2020 at 8:00 Am Edt BOSTON, MA / ACCESSWIRE / May 11, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the first quarter of 2020 ended March 31, 2020 and...

Read more

Tetra Bio-Pharma Engages energi PR as its Public Relations Firm

May 8, 2020 4:00 PM

OTTAWA, ON / ACCESSWIRE / May 8, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has engaged energi PR Inc. as its public relations firm, led by CEO, Carol Levine a seasoned public relations professional. The firm will concentrate on the implementation of a communication strategy including media...

Read more

Molecular Partners Confirms Ultra-Potent Inhibition of SARS-CoV-2 Live Virus by Anti-COVID-19 DARPin(R) Candidates

May 7, 2020 1:05 AM

DARPin® antiviral candidates demonstrate low picomolar potency in live virus assay Candidate construction complete; two candidates ready for preclinical development & manufacturing Therapeutic profile of a highly potent antiviral biologic with a long half-life supports both a prophylactic and therapeutic approach Initiation of clinical studies planned for H2 2020 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 7,...

Read more

Interim Management Statement Q1 2020: Continued Progress on Abicipar, Sharpened Focus on Pipeline Activities

May 7, 2020 1:00 AM

Research & Development Highlights: Abicipar in neovascular wet age-related macular degeneration (nAMD): Presentation of MAPLE data at the 2020 Angiogenesis, Exudation, and Degeneration symposium showed lower rates of intra-ocular inflammation than the rate observed in Phase 3 studies, as well as no incidences of retinal vasculitis In March, a filing for approval of abicipar in nAMD was submitted to the Japanese...

Read more

Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program

May 6, 2020 8:00 AM

OTTAWA, ON / ACCESSWIRE / May 6, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has now completed the modifications to the nonclinical safety program of PPP003 to ensure the launch of a Phase 1 trial in healthy volunteers later this year and subsequently be able to initiate a Phase 2 trial...

Read more